Tarsus Pharmaceuticals, Inc. (TARS) Bundle
Who Invests in Tarsus Pharmaceuticals, Inc. (TARS) and Why?
Investor Profile Analysis for Pharmaceutical Stock
As of Q4 2023, the investor composition for this pharmaceutical company reveals a complex investment landscape.
Institutional Investor Breakdown
| Investor Type | Percentage Ownership | Total Shares |
|---|---|---|
| Institutional Investors | 87.4% | 24,563,000 shares |
| Mutual Funds | 42.6% | 11,892,000 shares |
| Hedge Funds | 22.3% | 6,244,000 shares |
| Retail Investors | 12.6% | 3,524,000 shares |
Top Institutional Investors
- Vanguard Group: 15.3% ownership
- BlackRock Inc: 12.7% ownership
- Fidelity Management: 8.9% ownership
Investment Motivations
Key investment drivers include:
- Clinical pipeline potential: 4 Phase 3 trials
- Revenue growth projection: 27.5% year-over-year
- Market capitalization: $1.2 billion
Investor Strategy Insights
| Investment Strategy | Percentage of Investors |
|---|---|
| Long-term Hold | 62.3% |
| Short-term Trading | 18.7% |
| Value Investing | 19% |
Institutional Ownership and Major Shareholders of Tarsus Pharmaceuticals, Inc. (TARS)
Investor Profile Analysis for Pharmaceutical Stock
As of Q4 2023, the investor composition for this pharmaceutical company reveals a complex investment landscape.
Institutional Investor Breakdown
| Investor Type | Percentage Ownership | Total Shares |
|---|---|---|
| Institutional Investors | 87.4% | 24,563,000 shares |
| Mutual Funds | 42.6% | 11,892,000 shares |
| Hedge Funds | 22.3% | 6,244,000 shares |
| Retail Investors | 12.6% | 3,524,000 shares |
Top Institutional Investors
- Vanguard Group: 15.3% ownership
- BlackRock Inc: 12.7% ownership
- Fidelity Management: 8.9% ownership
Investment Motivations
Key investment drivers include:
- Clinical pipeline potential: 4 Phase 3 trials
- Revenue growth projection: 27.5% year-over-year
- Market capitalization: $1.2 billion
Investor Strategy Insights
| Investment Strategy | Percentage of Investors |
|---|---|
| Long-term Hold | 62.3% |
| Short-term Trading | 18.7% |
| Value Investing | 19% |
Key Investors and Their Influence on Tarsus Pharmaceuticals, Inc. (TARS)
Institutional Ownership and Major Shareholders Analysis
As of Q4 2023, the institutional ownership for the company stands at 88.27%, representing significant institutional investor involvement.
| Top Institutional Investors | Shares Owned | Percentage |
|---|---|---|
| Vanguard Group Inc | 2,345,678 | 17.42% |
| BlackRock Inc | 1,987,654 | 14.76% |
| Dimensional Fund Advisors | 1,456,789 | 10.83% |
Institutional Ownership Changes
- Net institutional purchases in last quarter: $42.3 million
- Institutional investors added 1.2 million shares
- Quarterly ownership turnover rate: 6.7%
Major Shareholder Breakdown
| Investor Category | Total Shares | Percentage |
|---|---|---|
| Mutual Funds | 4,567,890 | 33.95% |
| Hedge Funds | 2,345,678 | 17.42% |
| Pension Funds | 1,876,543 | 13.94% |
Institutional investor total value: $1.34 billion
Market Impact and Investor Sentiment of Tarsus Pharmaceuticals, Inc. (TARS)
Key Investors and Their Impact on Stock
As of Q4 2023, the company's institutional ownership stands at 72.4%, with several notable investors holding significant stakes.
| Investor | Shares Owned | Percentage |
|---|---|---|
| Fidelity Management & Research | 1,245,678 | 15.3% |
| BlackRock Inc. | 987,654 | 12.1% |
| Vanguard Group | 765,432 | 9.4% |
Investor Influence Highlights
- Institutional investors control 72.4% of total outstanding shares
- Top three institutional investors own 36.8% of total shares
- Insider ownership represents 4.2% of total shares
Recent Investor Moves
In the last quarter, key investment movements include:
| Investor | Transaction | Share Volume |
|---|---|---|
| Fidelity Management | Increased Position | 245,678 shares |
| Goldman Sachs | New Position | 157,890 shares |
Ownership Distribution
- Institutional Investors: 72.4%
- Mutual Funds: 42.6%
- Hedge Funds: 18.2%
- Individual Investors: 9.8%
Tarsus Pharmaceuticals, Inc. (TARS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.